Arena Pharma (ARNA) Dips; Enrollment Accelerated for Orexigen's (OREX) Contrave Trial
Tweet Send to a Friend
Up)
Arena Pharmaceuticals (Nasdaq: ARNA) is indicated lower Wednesday morning following a release from peer Orexigen (Nasdaq: OREX) that enrollment in the Light Study, the Contrave cardiovascular outcomes clinical trial, is going faster than expected.
Arena is bid about 2.8 percent lower.
Otherwise, VIVUS (Nasdaq: VVUS), which has its Qnexa slated for an upcoming PDUFA date with the FDA, is also bid slightly lower ahead of the bell.
For more color from Orexigen, click here.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Arena is bid about 2.8 percent lower.
Otherwise, VIVUS (Nasdaq: VVUS), which has its Qnexa slated for an upcoming PDUFA date with the FDA, is also bid slightly lower ahead of the bell.
For more color from Orexigen, click here.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: Fannie Mae, Freddie Mac Surge as Seriously Delinquent Rate Falls Below 3%
- Bulls and Bears Do Battle in Aeropostale (ARO); Turnaround Intact?
- Highway Holdings (HIHO) Surges, Halted on $400K Per Year Order
Create E-mail Alert Related Categories
FDA, Insiders' Blog, Momentum MoversComments
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
really...
ryan on Jul 11, 2012 07:38 AMMark as Spam | Reply to this comment
this has to be the dumbest, most ill informed article I've seen in awhile. that is all. :)